Last December, the Food and Drug Administration (FDA) approved Radiesse, an injectable filler to correct signs of facial lipoatrophy (loss of fat) in HIV+ people. Until now, Sculptra was the only facial filler approved by the FDA for this condition. Radiesse contains a synthetic (or man-made) version of calcium hydroxylapatite, a substance found in bones and teeth. When Radiesse is injected into the skin, natural collagen forms around the calcium hydroxylapatite. As a result, the skin becomes thicker and conceals the hollows in the thee associated with lipoatrophy. Common side effects include bruising, swelling, pain, and redness at the injection side, which are usually temporary and mild in nature. There is also the small possibility of infection at the injection site. Radiesse is considered to be a temporary filler and treatment may need to be repeated within a tow years to maintain results.